Summary: Troglitazone is an insulin sensitizer and also known as an agonist of peroxisome proliferatoractivated receptor-g (PPARg). In the present study, we have studied the in‰uence of troglitazone on CYP3A form expressions in HepG2 cells for a model of human tissue. Interestingly, constitutively expressed forms of cytochrome P450, CYP3A5 and CYP3A7, were suppressed by the pretreatment of troglitazone but not of the related thiazolidinediones, pioglitazone and rosiglitazone in this cell line. A major liver CYP3A form, CYP3A4, was not detected in this cell line with and without troglitazone treatment. The troglitazone-mediated suppressions of CYP3A5 and CYP3A7 were found to be independent of expression levels of nuclear transcriptional factors, PXR, RXRa and PPARg. These results suggest that the selectively suppressive eŠects of troglitazone on CYP3A5 and CYP3A7 expressions may be caused by a novel pathway.
Introduction
The human cytochrome P450 3A (CYP3A) subfamily includes mainly three forms, CYP3A4, CYP3A5 and CYP3A7. Notably, CYP3A4 is a major P450 form in human livers and intestines. CYP3A4 is involved in metabolism of endogenous and exogenous compounds, and its expression is enhanced by treatment with chemicals such as rifampicin, clotrimazole or phenobarbital. 1) Troglitazone has recently been shown to increase human urinary excretion of 6b-hydroxycortisol 2) and also the expression level of CYP3A protein in primary cultures of human hepatocytes. 3) Troglitazone has been used as an oral antidiabetic drug for treatment of type II diabetes 4) and is also known as an agonist of the peroxisome proliferator-activated receptor-g (PPARg), a nuclear transcriptional factor. 5) However, the mechanism enhancing the human CYP3A form remains obscure.
The induction of CYP3A form in human-derived cell lines has been studied for models of human tissues. [6] [7] [8] [9] HepG2 cells are one of most useful cell lines as a human liver model because of the well-diŠerentiated function of this human hepatoblastoma. Thus, we have examined the in‰uence of troglitazone on microsomal CYP3A expression in HepG2 cells as the tool.
Materials and Methods

Chemicals
Troglitazone, pioglitazone and rosiglitazone were kindly donated by Sankyo Co. Ltd. (Tokyo, Japan). Rifampicin was purchased from Sigma (St. Louis, MO).
Cell Culture
Human hepatoma, HepG2 cells, were maintained in Dulbecco's modiˆed Eagle's high-glucose medium supplemented with antibiotic-antimycotic solution (GIBCO BRL, Rockville, MD), MEM nonessential amino acid solution (GIBCO BRL) and 10z fetal bovine serum (FBS, Boehringer Mannheim, Germany) at 379 C under an atmosphere of 5z CO2. HepG2 cells were seeded at 1.0×10 6 per well in 6-well plates, and cultured for 24 h. The medium was changed into FBS-free, but contained chemicals (10 mM in Fig. 1 and 1 mM andW or 10 mM in Fig. 2 ) or dimethylsulfoxide (DMSO,ˆnal 0.1z) as vehicle for a successive 48 h.
RT-PCR
Total RNAs were isolated by the AGPC method. 10) To conˆrm the quality of RNA, the total RNAs were separated by electrophoresis in a denaturing 1z agarose gel. Reverse transcriptase reactions were carried out us- Biotech, Uppsala, Sweden) according to the manufacturer's instructional protocol. PCR reactions were performed in a 30 ml reaction mixture containing 10 pmol each primer, 250 mM dNTP mixture, 1.5 units of Taq DNA polymerase (Takara, Kyoto, Japan), 3 ml of 10× reaction buŠer and 2 ml of theˆrst-strand cDNA as a template. PCR condition and primer sequences are shown in Table 1 . The oligonucleotids for PCR primers were synthesized and provided by Nihon Gene Research Lab. Inc. (Sendai, Japan). PCR products were separated in a 1z agarose W 1×TBE gel containing ethidium bromide.
Western Blotting
Western blotting was carried out according to the method as reported previously. 11) Microsomal proteins (50 mg from HepG2 cells) were separated by SDS-PAGE using 8z gel. The blotted membrane was probed with a polyclonal anti-human CYP3A antibody 12) and developed by an alkaline phosphatase method.
13) The visualized bands were scanned and the intensities were calculated by use of the NIH Image software (version 1.59).
Results
To examine whether CYP3A protein expressions are altered by the treatment of HepG2 cells with troglitazone, microsomal CYP3A protein levels were analyzed by Western blotting (Fig. 1(A) ). Human CYP3A protein content was decreased in the microsomal fraction from troglitazone-treated HepG2 cells (about 35z of control), although it was increased by the pretreatment with rifampicin, a typical CYP3A4 inducer. The CYP3A content was, however, unaltered by the treatments with other thiazolidinedione compounds, pioglitazone or rosiglitazone. Moreover, troglitazoneinduced decrease of the CYP3A protein expression was not reversed fully by simultaneous treatment with rifampicin ( Fig. 1(B) ). These results suggest the selective suppression of the CYP3A expression by troglitazone, but not by pioglitazone and rosiglitazone in HepG2 cells.
Identiˆcation of CYP3A forms in HepG2 cells was Table 1 ). The speciˆcity of these primers was conˆrmed by PCR using subcloned human CYP3A cDNAs (pCMV3A4, pCMV3A5 and pCMV3A7) as templates.
As shown in Fig. 2(A) , these primers detected only a designated CYP3A form, without a cross-ampliˆcation under this PCR condition. A major adult human CYP3A form, CYP3A4 was not detected in HepG2 cells with or without pretreatment of rifampicin in the PCR experiment, which was in contrast to a previous study. 6) Similar results were also obtained with troglitazone ( Fig. 2(B) ). These results may indicate a functional defect of the CYP3A4 expression and W or induction by troglitazone and rifampicin in HepG2 cells used in this experiment. On the other hand, CYP3A7, a fetal CYP3A form, was constitutively expressed in HepG2 cells. The CYP3A7 expression was decreased by the pretreatment with 10 mM of troglitazone, but was retained by simultaneous treatment with rifampicin and troglitazone (10 mM) (Fig. 2(B) ). Another form, CYP3A5, was weakly expressed in HepG2 cells. The CYP3A5 expression is decreased by treatment of 10 mM of troglitazone similar to that observed with CYP3A7. Although the CYP3A5 expression was enhanced by the treatment with rifampicin in HepG2, the rifampicin induction was not reversed in the presence of 10 mM of troglitazone (data not shown). These results conˆrm that the CYP3A forms suppressed in troglitazonetreated HepG2 cells are CYP3A7 and CYP3A5, but not CYP3A4. A steroid receptor, PXR (pregnane X receptor), has been reported to be a key regulator of CYP3A4 and CYP3A7 genes transactivations triggered by chemicals such as rifampicin.
7,14-16) Thus, we examined whether or not troglitazone decreases PXR expression. The PXR mRNA was constitutively detected and the levels of that were not in‰uenced by the pretreatment with troglitazone and W or rifampicin in HepG2 cells (Fig. 2(B) ). In addition, speciˆc mRNA levels of PPARg were also not in‰uenced by the treatment of troglitazone in HepG2 cells. Furthermore, speciˆc mRNA levels of retinoid X receptora (RXRa), which is a heterodimer partner of PXR and PPARg, were not changed by this treatment (Fig. 2(B) ).
Discussion
Hepatic dysfunction by troglitazone is a more serious problem than by other thiazolidinediones (TZDs).
4) It is also reported that troglitazone, but not rosiglitazone, induces human liver CYP3A4. 4) Camp et al. showed the distinct regulation of several genes by treatment with troglitazone and rosiglitazone in HepG2 cells using twodimensional protein gel electrophoresis. 17) They demonstrated the decreased expression of at least three proteins by troglitazone but not by rosiglitazone. These data suggest the distinct in‰uences of these two TZDs. However, the reason that causes the diŠerence among TZDs is not yet well understood.
In the present study, we have examined the in‰uence of TZDs on expression of the human CYP3A forms in HepG2 cells. Interestingly, expression of CYP3A7 was suppressed in troglitazone-treated HepG2 cells but not in cells treated with other TZDs, pioglitazone or rosiglitazone. The suppression was observed at both protein and mRNA levels, and thus troglitazone possibly aŠects the transcriptional regulation of the CYP3A7 gene. PXR, which is a transactivator of the CYP3A7 gene, 16) exists in HepG2 cells (Fig. 2(B) ) and troglitazone is one of the activators of PXR. 18) Nevertheless, CYP3A7 was suppressed by treatment of troglitazone in HepG2 cells. This suppression was not caused by downregulation of PXR, PPARg and RXRa as shown in Fig. 2(B) . Therefore, the suppression of CYP3A7 is likely to be caused by a novel pathway.
CYP3A5 expression was also suppressed in troglitazone-treated HepG2 cells. The suppression was not restored by simultaneous treatment with rifampicin, although the CYP3A7 supression by troglitazone was restored by the same treatment. Thus, the reason for the incomplete recovery of CYP3A content may be the lack of CYP3A5 induction capability in troglitazone-and rifampicin-treated HepG2 cells.
In the present study, using speciˆc probes for RT-PCR, we found that HepG2 cells constitutively express a fetal CYP3A form, CYP3A7, and CYP3A5. These expressed levels were enhanced by treatment with rifampicin (data not shown). On the other hand, the present experiment has also shown that CYP3A4 is scarcely expressed and not enhanced by treatment with rifampicin and TZDs in spite of the presence of PXR in this cell-line. Recently, data supporting our undetectable expression level of CYP3A4 mRNA in HepG2 cells have been reported. 19) Therefore, HepG2 cells may be a suitable model and tool for study of CYP3A5 or CYP3A7 regulation rather than CYP3A4.
In conclusion, we have shown the selective suppressive eŠect of troglitazone on CYP3A5 and CYP3A7 expressions in HepG2 cells without the down regulation of transcription factors such as PXR, PPARg and RXRa. This is likely to be caused by a novel pathway.
